2019
|
|

Abstract: Aims To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monotherapy. Materials and methods This multinational, active‐controlled, parallel‐group phase 3b trial randomized 461 patients, at least 18 years of age, with glycated haemoglobin (HbA1c) of 8%–10.5% (64–91 mmol/mol), to… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
1
0
8
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

0
8
0
Order By: Relevance
“…Taken together, these data suggest that dapagliflozin might indeed be superior to sitagliptin for the cardiometabolic effects. In addition, previous studies reported the preferable cardiometabolic effects regarding SGLT2 inhibitors [36][37][38][39]. Dapagliflozin also showed stronger therapeutic effects on other indices that might contribute to the prevention of cardiovascular events.…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Taken together, these data suggest that dapagliflozin might indeed be superior to sitagliptin for the cardiometabolic effects. In addition, previous studies reported the preferable cardiometabolic effects regarding SGLT2 inhibitors [36][37][38][39]. Dapagliflozin also showed stronger therapeutic effects on other indices that might contribute to the prevention of cardiovascular events.…”
Section: Discussionmentioning
“…This combination has been suggested as a potential early glucose-lowering treatment of type 2 diabetes due to their complementing mechanism of action (142). Clinical studies have also verified augmented glucose-lowering action of this combination in association with low risk for hypoglycemia (115, 143, 144).…”
Section: Current Status and Future Outlookmentioning
“…A PubMed search conducted in July 2019 identified 15 studies in which SGLT-2 inhibitors were used early in the course of T2D [64, 8597]. Ten studies evaluated dapagliflozin [64, 8589, 91, 93, 94, 98], two studied canagliflozin [90, 97], two assessed empagliflozin [92, 96], and one evaluated ertugliflozin [95]. Seven studies investigated SGLT-2 inhibitors as monotherapy [8590, 98], while, in eight studies, SGLT-2 inhibitors were given in combination with metformin (Table 2) [64, 9197].…”
Section: Place Of Sglt-2 Inhibitors In Early Diabetes Therapymentioning
“…Two studies have also demonstrated that the magnitude of the change in HbA1c with an SGLT-2 inhibitor, with or without metformin, was similar in treatment-naive patients as in patients who had already received metformin [92] or insulin with metformin, pioglitazone, or rosiglitazone [86]. In a study of patients with T2D receiving stable metformin therapy, early addition of dapagliflozin plus saxagliptin was associated with a significantly greater reduction in HbA1c after 26 weeks compared with addition of sitagliptin ( p = 0.0008); the between-group difference in HbA1c reduction increased at 52 weeks [93]. Similarly, in the 52-week Evaluation of Ertugliflozin Efficacy and Safety Factorial (VERTIS FACTORIAL) study, significantly greater HbA1c reductions were observed with the combination of ertugliflozin plus sitagliptin as add-on therapy to metformin versus those with either agent individually after 26 weeks of treatment ( p < 0.001), with sustained HbA1c reductions at 52 weeks [95].…”
Section: Place Of Sglt-2 Inhibitors In Early Diabetes Therapymentioning